Vertex Pharmaceutic (VRTX) 92.05 $VRTX
Vertex Announces Presentations of Data for KALYDECO(R) (ivacaftor) and ORKAMBI(R) (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
BusinessWire - 1 hr 13 mins ago
---Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS-
VRTX: 92.05 (-0.44)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.07%
Comtex SmarTrend(R) - Thu Jun 09, 3:17PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 92.05 (-0.44)
After Yesterday's Decline of 2.07%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jun 09, 3:15PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 92.05 (-0.44)
5 Toxic Stocks to Discard from Your Portfolio Right Now
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:27AM CDT
Identifying toxic stocks on a regular basis and removing them from one's portfolio is a secret to investing success.
VRTX: 92.05 (-0.44), ZLTQ: 28.93 (-0.43), ULTI: 205.49 (-2.85), LGF: 21.33 (-0.53), CRM: 82.22 (-0.51)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.70 (-3.76), VRTX: 92.05 (-0.44), PXD: 160.75 (-3.45), ALXN: 136.16 (-2.08), HAL: 44.80 (-0.70), EOG: 82.71 (-1.87), AMGN: 154.98 (-1.80), ILMN: 141.43 (-1.99), XOM: 90.28 (-0.39), COP: 45.30 (-1.27), JUNO: 43.92 (-1.61), CVX: 102.20 (-0.61), OXY: 75.28 (-0.32), REGN: 373.07 (-8.01)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 246.70 (-3.76), VRTX: 92.05 (-0.44), GILD: 84.71 (-1.06), SRPT: 20.00 (-0.99), ICPT: 151.00 (-3.22), ABBV: 60.73 (-0.02), IONS: 21.69 (+0.24)
Vertex (VRTX) Orkambi sNDA Accepted with Priority Review
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:28AM CDT
Vertex (VRTX) announced that the FDA has accepted an sNDA for Orkambi for the treatment of CF, in children (aged 6 to 11 years) who have two copies of the F508del mutation.
VRTX: 92.05 (-0.44), ANIP: 52.54 (-1.15), PFE: 35.31 (unch), BMY: 72.94 (+0.21)
Vertex to Present at the Goldman Sachs Healthcare Conference on June 7
BusinessWire - Tue May 31, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde, CA on Tuesday, June 7th at 1:40 p.m. ET (10:40 a.m. PT).
VRTX: 92.05 (-0.44)
Vertex Pharmaceuticals Rises 2.94% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:33PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.61 to a high of $93.60. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $90.49 on volume of 665,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 92.05 (-0.44)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 2.94% Yesterday
Comtex SmarTrend(R) - Tue May 31, 2:31PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.61 to a high of $93.60. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $90.49 on volume of 665,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 92.05 (-0.44)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 10.48 (-0.42), VRTX: 92.05 (-0.44), VZ: 52.78 (+0.83), NVDA: 46.67 (-0.71), CELGZ: 1.46 (-0.04), CELG: 103.81 (-2.32)
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI(R) (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation
BusinessWire - Tue May 31, 6:58AM CDT
---Target review date of September 30, 2016 set for the FDA's decision on the application-
VRTX: 92.05 (-0.44)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 1.02% Rise
Comtex SmarTrend(R) - Fri May 27, 12:44PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.37 to a high of $90.49. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $89.93 on volume of 528,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 92.05 (-0.44)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 92.05 (-0.44), HZNP: 18.21 (-0.32), ICPT: 151.00 (-3.22), ABBV: 60.73 (-0.02), ACOR: 27.39 (-0.13), BIOD: 0.35 (+0.01), XNPT: 7.00 (unch)
Spero Therapeutics Acquires Novel Gyrase Inhibitors from Vertex Pharmaceuticals
PR Newswire - Wed May 25, 7:00AM CDT
Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced that it has entered into an agreement with Vertex Pharmaceuticals to acquire worldwide rights to VXc-486/VXc-100 and a portfolio of innovative antibacterial compounds targeted at bacterial gyrase (GyrB) and/or topoisomerase IV (ParE).
VRTX: 92.05 (-0.44)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 60.07 (-0.03), TRVN: 6.95 (-0.27), TTPH: 3.95 (-0.16), VRTX: 92.05 (-0.44), ADRO: 12.32 (-0.10), AMGN: 154.98 (-1.80), ANAC: 99.11 (+0.03)
Vertex Announces Presentations of Data for KALYDECO(R) (ivacaftor) and ORKAMBI(R) (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
BusinessWire - 1 hr 13 mins ago
---Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS-
VRTX: 92.05 (-0.44)
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.07%
Comtex SmarTrend(R) - Thu Jun 09, 3:17PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 92.05 (-0.44)
After Yesterday's Decline of 2.07%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jun 09, 3:15PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $92.18 to a high of $94.55. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $92.47 on volume of 421,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 92.05 (-0.44)
5 Toxic Stocks to Discard from Your Portfolio Right Now
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:27AM CDT
Identifying toxic stocks on a regular basis and removing them from one's portfolio is a secret to investing success.
VRTX: 92.05 (-0.44), ZLTQ: 28.93 (-0.43), ULTI: 205.49 (-2.85), LGF: 21.33 (-0.53), CRM: 82.22 (-0.51)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.70 (-3.76), VRTX: 92.05 (-0.44), PXD: 160.75 (-3.45), ALXN: 136.16 (-2.08), HAL: 44.80 (-0.70), EOG: 82.71 (-1.87), AMGN: 154.98 (-1.80), ILMN: 141.43 (-1.99), XOM: 90.28 (-0.39), COP: 45.30 (-1.27), JUNO: 43.92 (-1.61), CVX: 102.20 (-0.61), OXY: 75.28 (-0.32), REGN: 373.07 (-8.01)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 246.70 (-3.76), VRTX: 92.05 (-0.44), GILD: 84.71 (-1.06), SRPT: 20.00 (-0.99), ICPT: 151.00 (-3.22), ABBV: 60.73 (-0.02), IONS: 21.69 (+0.24)
Vertex (VRTX) Orkambi sNDA Accepted with Priority Review
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:28AM CDT
Vertex (VRTX) announced that the FDA has accepted an sNDA for Orkambi for the treatment of CF, in children (aged 6 to 11 years) who have two copies of the F508del mutation.
VRTX: 92.05 (-0.44), ANIP: 52.54 (-1.15), PFE: 35.31 (unch), BMY: 72.94 (+0.21)
Vertex to Present at the Goldman Sachs Healthcare Conference on June 7
BusinessWire - Tue May 31, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde, CA on Tuesday, June 7th at 1:40 p.m. ET (10:40 a.m. PT).
VRTX: 92.05 (-0.44)
Vertex Pharmaceuticals Rises 2.94% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:33PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.61 to a high of $93.60. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $90.49 on volume of 665,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 92.05 (-0.44)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 2.94% Yesterday
Comtex SmarTrend(R) - Tue May 31, 2:31PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.61 to a high of $93.60. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $90.49 on volume of 665,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 92.05 (-0.44)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 10.48 (-0.42), VRTX: 92.05 (-0.44), VZ: 52.78 (+0.83), NVDA: 46.67 (-0.71), CELGZ: 1.46 (-0.04), CELG: 103.81 (-2.32)
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI(R) (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation
BusinessWire - Tue May 31, 6:58AM CDT
---Target review date of September 30, 2016 set for the FDA's decision on the application-
VRTX: 92.05 (-0.44)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 1.02% Rise
Comtex SmarTrend(R) - Fri May 27, 12:44PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.37 to a high of $90.49. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $89.93 on volume of 528,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 92.05 (-0.44)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 92.05 (-0.44), HZNP: 18.21 (-0.32), ICPT: 151.00 (-3.22), ABBV: 60.73 (-0.02), ACOR: 27.39 (-0.13), BIOD: 0.35 (+0.01), XNPT: 7.00 (unch)
Spero Therapeutics Acquires Novel Gyrase Inhibitors from Vertex Pharmaceuticals
PR Newswire - Wed May 25, 7:00AM CDT
Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced that it has entered into an agreement with Vertex Pharmaceuticals to acquire worldwide rights to VXc-486/VXc-100 and a portfolio of innovative antibacterial compounds targeted at bacterial gyrase (GyrB) and/or topoisomerase IV (ParE).
VRTX: 92.05 (-0.44)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 60.07 (-0.03), TRVN: 6.95 (-0.27), TTPH: 3.95 (-0.16), VRTX: 92.05 (-0.44), ADRO: 12.32 (-0.10), AMGN: 154.98 (-1.80), ANAC: 99.11 (+0.03)
